← All trials
NCT05710094
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 19, 2021
- Primary completion
- Aug 19, 2022
- Completion date
- Aug 19, 2022
- First posted
- Feb 2, 2023
- Last posted
- Feb 2, 2023
- Enrollment
- 28
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- SoftOx Solutions A/SLead sponsor
- University Hospital Bispebjerg and FrederiksbergOverall official - principal investigator
- SoftOx Solutions A/SStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.